Sensei Biotherapeutics, Inc. (NASDAQ:FTH) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) has earned an average rating of “Moderate Buy” from the thirteen brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $55.00.

A number of equities research analysts have weighed in on FTH shares. Robert W. Baird initiated coverage on Sensei Biotherapeutics in a report on Friday, June 26th. They set an “outperform” rating and a $57.00 price objective on the stock. Oppenheimer assumed coverage on Sensei Biotherapeutics in a research note on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 price target on the stock. BTIG Research reiterated a “buy” rating and set a $55.00 price objective on shares of Sensei Biotherapeutics in a research note on Thursday, July 16th. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Sensei Biotherapeutics in a report on Tuesday, August 11th. Finally, JonesTrading assumed coverage on shares of Sensei Biotherapeutics in a report on Tuesday, August 4th. They issued a “buy” rating and a $55.00 target price on the stock.

Insider Transactions at Sensei Biotherapeutics

In other news, CFO Brian C. Stephenson acquired 9,391 shares of the firm’s stock in a transaction on Wednesday, June 24th. The shares were purchased at an average cost of $26.13 per share, with a total value of $245,386.83. Following the completion of the purchase, the chief financial officer owned 26,804 shares of the company’s stock, valued at $700,388.52. This represents a 53.93% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Anand Kiran Parikh acquired 2,806 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were purchased at an average cost of $19.76 per share, with a total value of $55,446.56. Following the acquisition, the chief executive officer owned 764,234 shares of the company’s stock, valued at approximately $15,101,263.84. This represents a 0.37% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders acquired 49,494 shares of company stock worth $1,188,822. Company insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Sensei Biotherapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of FTH. Renaissance Technologies LLC increased its stake in shares of Sensei Biotherapeutics by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after buying an additional 1,100 shares in the last quarter. Bank of America Corp DE lifted its position in Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after buying an additional 32,719 shares in the last quarter. Stempoint Capital LP bought a new stake in Sensei Biotherapeutics during the 1st quarter worth about $4,188,000. Alyeska Investment Group L.P. acquired a new stake in Sensei Biotherapeutics in the 2nd quarter valued at about $3,610,000. Finally, Vivo Capital LLC acquired a new stake in Sensei Biotherapeutics in the 1st quarter valued at about $22,758,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Price Performance

Shares of NASDAQ:FTH opened at $33.84 on Monday. The business has a 50-day moving average of $28.53. The firm has a market capitalization of $874.43 million, a PE ratio of -0.24 and a beta of -0.25. Sensei Biotherapeutics has a fifty-two week low of $7.45 and a fifty-two week high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.04) by $2.20. As a group, equities analysts forecast that Sensei Biotherapeutics will post -13.18 earnings per share for the current fiscal year.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.